Cariprazine

Contraindicated

Cariprazine Bromopride Explained Increased risk of extrapyramidal reactions Details Cariprazine Ensitrelvir Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Cariprazine Metoclopramide Explained An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details Cariprazine Metoclopramide Injection Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details Cariprazine Metoclopramide Nasal Spray Gimoti An increased risk of extrapyramidal reactions and neuroleptic malignant syndrome Details

Major

Cariprazine Buprenorphine Belbuca Explained Increased risk of respiratory and CNS depression Details Cariprazine Relugolix Orgovyx Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Cabergoline Dostinex® Explained Reduced efficacy of cabergoline and reduced efficacy of dopamine-2 receptors Details Cariprazine Adagrasib Krazati Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Cariprazine Amprenavir Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Apalutamide Erleada Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Aprepitant Aponvie Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Armodafinil Nuvigil Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Atazanavir Reyataz Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Avacopan Tavneos Explained Increased CYP3A4 substrate exposure Details Cariprazine Belzutifan Welireg Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Berotralstat Orladeyo Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Bexarotene Targretin Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Boceprevir Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Cariprazine Bosentan Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Brigatinib Alunbrig Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Brivaracetam Briviact Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Carbamazepine Carbatrol Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Cenobamate Xcopri Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Ceritinib Zykadia Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Cariprazine Ciprofloxacin Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure and an increased risk of QT prolon... Details Cariprazine Clarithromycin Biaxin Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Cariprazine Clobazam Onfi Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Clofazimine Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Cobicistat Tybost Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Cariprazine Conivaptan Vaprisol Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Crizotinib Xalkori Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Dabrafenib Tafinlar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Darolutamide Nubeqa Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Darunavir Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Dexamethasone Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Dicloxacillin Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Diltiazem Cardizem Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Cariprazine Dipyrone Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Cariprazine Dronedarone Multaq Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details